Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Enzinger

Showing results (171-180 of 199) with videos related to

Pageof 20
Sort By:
Neuroimage|June 27, 2008
Reproducibility of fMRI in the clinical setting: implications for trial designsR Bosnell, C Wegner, Z T Kincses, et al.
The Lancet. Oncology|February 6, 2019
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trialCharles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, et al.
Journal for Immunotherapy of Cancer|June 21, 2023
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humansVictoire Cardot-Ruffino, Naima Bollenrucher, Luisa Delius, et al.
Nature Communications|August 9, 2024
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinomaHarshabad Singh, Kristen E Lowder, Kevin Kapner, et al.
Neuroimage|January 13, 2009
Short-term adaptation to a simple motor task: a physiological process preserved in multiple sclerosisL Mancini, O Ciccarelli, F Manfredonia, et al.
Cancer|March 27, 2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trialJames M Cleary, Nora K Horick, Nadine Jackson McCleary, et al.
JCO Precision Oncology|June 21, 2023
Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI CancerHarshabad Singh, Samuel J Klempner, Nelya Melnitchouk, et al.
Journal for Immunotherapy of Cancer|October 1, 2021
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survivalLeonie K de Klerk, Anuj K Patel, Sarah Derks, et al.
JAMA Oncology|March 16, 2018
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 TrialCharles S Fuchs, Toshihiko Doi, Raymond W Jang, et al.
Cancers|March 10, 2022
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II StudiesManish A Shah, Anghel Adrian Udrea, Igor Bondarenko, et al.
Pageof 20

Showing results (171-180 of 199) with videos related to

Sort By:
Pageof 20
Neuroimage|June 27, 2008
Reproducibility of fMRI in the clinical setting: implications for trial designsR Bosnell, C Wegner, Z T Kincses, et al.
The Lancet. Oncology|February 6, 2019
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trialCharles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, et al.
Journal for Immunotherapy of Cancer|June 21, 2023
G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humansVictoire Cardot-Ruffino, Naima Bollenrucher, Luisa Delius, et al.
Nature Communications|August 9, 2024
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinomaHarshabad Singh, Kristen E Lowder, Kevin Kapner, et al.
Neuroimage|January 13, 2009
Short-term adaptation to a simple motor task: a physiological process preserved in multiple sclerosisL Mancini, O Ciccarelli, F Manfredonia, et al.
Cancer|March 27, 2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trialJames M Cleary, Nora K Horick, Nadine Jackson McCleary, et al.
JCO Precision Oncology|June 21, 2023
Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI CancerHarshabad Singh, Samuel J Klempner, Nelya Melnitchouk, et al.
Journal for Immunotherapy of Cancer|October 1, 2021
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survivalLeonie K de Klerk, Anuj K Patel, Sarah Derks, et al.
JAMA Oncology|March 16, 2018
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 TrialCharles S Fuchs, Toshihiko Doi, Raymond W Jang, et al.
Cancers|March 10, 2022
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II StudiesManish A Shah, Anghel Adrian Udrea, Igor Bondarenko, et al.
Pageof 20